Navigation Links
Attention: Extra-hepatic manifestation of hepatitis C virus infection
Date:1/16/2008

In 1994, the team of Tchernev and Petrova from Alexandrovska Hospital in Sofia examined a female patient with liver cirrhosis caused by chronic Hepatitis C virus (HCV). They were intrigued by the patient's many extra-hepatic manifestations -- vascular lesions on the lower limbs, acute pain in the joints, intense tingling of the fingers, and extreme labor-impairing fatigue. They were also intrigued by the presence of cryoglobulins in the patient's blood. Two years later, the patient developed enlarged lymph nodes on the neck. When one of the nodes was histologically tested, the patient was found to have lymphoma.

This case spurred the interest of the investigators in the extra-hepatic manifestations and complications of HCV infection, and for over a decade they studied the links between HCV infection, cryoglobulinemia, and lymphoma.

A research article published on December 28, 2007 in the World Journal of Gastroenterology addresses this problem. In a study of 136 Bulgarian patients with HCV, the team of Tchernev and Petrova found 76.5% of the patients had extra-hepatic manifestations. Common manifestations were fatigue (59.6%), renal impairment (25%), type 2 diabetes (22.8%), paresthesia (19.9%), arthralgia (18.4%), and purpura predominantly of the lower limbs (17.6%). Over 37% of the patients had cryoglobulins, and 8.8% had B-cell lymphoma.

The study found positive links between the presence of extra-hepatic manifestations and age, female gender, duration of the infection, infection by transfusion of blood and blood products, and extensive liver fibrosis. Therefore, elderly women with chronic HCV and advanced liver fibrosis, who were infected by transfusion during childbirth, are at the highest risk of developing extra-hepatic manifestations of HCV infection.

The study also showed most extra-hepatic manifestations of HCV infection are associated with the presence of cryoglobulins. In particular, the risks of developing B-cell non-Hodgkin lymphoma are much higher in cryoglobulin-positive than in cryoglobulin-negative patients. In the study, 17.6% of cryoglobulin-positive patients had lymphoma, whereas only 3.5% of cryoglobulin-negative patients did.

Given the prevalence of HCV around the world, it is important for physicians to recognize the extra-hepatic signs and symptoms of HCV infection. Patients who exhibit such manifestations should be tested for HCV infection. This can lead to prompt diagnosis and effective treatment of the infection before the development of cryoglobulinemia, when treatment gives poor results or is ineffective.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. EHE International Supports the American Liver Foundations Efforts at Raising Awareness for Hepatitis
3. Standard Hepatitis B Treatment Bested by Newcomer
4. No Link Between Hepatitis B Shot, MS: Study
5. Treating patients with psychiatric disorders for hepatitis C
6. The American Liver Foundation Encourages Heightened Awareness of Hepatitis B and C in Light of Recent Events in the News
7. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
8. Most UK citizens susceptible to hepatitis B infection
9. Interferon does not slow or stop hepatitis C from worsening, study finds
10. Hepatitis C treatment reduces the virus but serious liver problems may progress
11. HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... West Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at ... FACS , will be taking part in the 2017 London Marathon. Set to take place ... variety of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Brady ... that its B-595 and B-7569 vinyl label materials received certification ... warning labels are tested to remain intact and legible, for use on chemical drums ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
(Date:4/21/2017)... ... 21, 2017 , ... Metrasens is honoured to have won ... most prestigious award for business success. The company has been recognized for ... grown by a total of 400% over the last six years. , Metrasens ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: